Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -4.11M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 600
Avg Vol 1,408
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 37%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surg...

Phone: 781 552 4452
Address:
2 Burlington Woods Drive, Suite 100, Burlington, United States
Latest News on BBLGW
Bone Biologics achieves 29-month shelf life for rhNELL-1

2026-05-19T12:10:05.000Z - 6 weeks ago

Bone Biologics achieves 29-month shelf life for rhNELL-1


Bone Biologics summarizes key milestones achieved during 2025

2026-01-08T13:40:29.000Z - 6 months ago

Bone Biologics summarizes key milestones achieved during 2025


Why Is Bone Biologics Stock (BBLG) Up 100% Today?

2025-06-27T12:25:15.000Z - 1 year ago

Why Is Bone Biologics Stock (BBLG) Up 100% Today?


Bone Biologics regains compliance with Nasdaq listing

2025-06-26T20:25:38.000Z - 1 year ago

Bone Biologics regains compliance with Nasdaq listing


Bone Biologics files $35M mixed securities shelf

2025-06-24T21:05:27.000Z - 1 year ago

Bone Biologics files $35M mixed securities shelf


Bone Biologics Corp trading halted, news pending

2025-06-09T23:50:10.000Z - 1 year ago

Bone Biologics Corp trading halted, news pending


Bone Biologics announces 1-for-6 reverse stock split

2025-06-06T12:15:30.000Z - 1 year ago

Bone Biologics announces 1-for-6 reverse stock split


Bone Biologics Announces 1-for-6 Reverse Stock Split

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Bone Biologics Announces 1-for-6 Reverse Stock Split


Bone Biologics reports progress with NB1 clinical program

2024-03-01T13:06:39.000Z - 2 years ago

Bone Biologics reports progress with NB1 clinical program


Bone Biologics Reports Progress With NB1 Clinical Program

Mar 1, 2024, 8:00 AM EST - 2 years ago

Bone Biologics Reports Progress With NB1 Clinical Program


Bone Biologics Corp trading halted, news pending

2023-12-20T00:50:00.000Z - 2 years ago

Bone Biologics Corp trading halted, news pending


Bone Biologics announces 1-for-8 reverse stock split

2023-12-18T13:12:24.000Z - 2 years ago

Bone Biologics announces 1-for-8 reverse stock split


Bone Biologics Announces 1-for-8 Reverse Stock Split

Dec 18, 2023, 8:00 AM EST - 2 years ago

Bone Biologics Announces 1-for-8 Reverse Stock Split


Bone Biologics Prices $5.0 Million Underwritten Public Offering

Jun 14, 2023, 11:30 PM EDT - 3 years ago

Bone Biologics Prices $5.0 Million Underwritten Public Offering


Bone Biologics Effects 1-for-30 Reverse Stock Split

Jun 6, 2023, 1:00 PM EDT - 3 years ago

Bone Biologics Effects 1-for-30 Reverse Stock Split


Bone Biologics CEO Issues Letter to Stockholders

Oct 25, 2022, 8:00 AM EDT - 4 years ago

Bone Biologics CEO Issues Letter to Stockholders